智通财经APP获悉，维亚生物(01873)午后涨超20%。截至发稿，涨19.59%，报1.77港元，成交额3201.24万港元。
消息面上，近日，维亚生物与西点药业达成AI驱动的反向寻靶研发合作。依托维亚生物的Mol2MARS平台，双方围绕药物分子潜在作用机制与靶点系统研究，构建了“AI计算+实验验证”的创新靶点发现研发闭环，为药物的作用机制解析与适应症拓展提供了新的科学依据。
招商证券指出，截至2026年上半年，CADD/AIDD累计参与项目228个、采购客户92家；AI参与赋能项目收入占CRO收入约14.0%、AI客户相关湿实验收入占比约15.0%。公司升级推出MARS多模态综合算法平台，在多肽、环肽及复杂大环化合物领域构建显著技术壁垒，并全面升级三大底层模块。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.